Oncobit AG

Oncobit is a spinoff from the University Hospital of Zurich and has developed a scalable and data-driven cancer monitoring platform based on the quantitative and sensitive detection of cancer markers in liquid biopsies for a tight monitoring of the patient’s cancer and an optimised therapy management. Its USP is a cloud based data analysis and interpretation software that was trained on healthy and patient data and ensures a robust and standardised reporting of results. With an initial emphasis on melanoma (already IVDR certified), Oncobit has generated significant traction in Europe including initial commercial contracts with a global pharmaceutical company and a first hospital in Switzerland, as well as the implementation of its products in three leading cancer centres in Germany.